| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
65,090,000 |
| Market
Cap: |
266.87(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.000001 - $0.05 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Acura Pharmaceuticals is a drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. Co. has discovered and developed three proprietary platform technologies which can be used to develop multiple products. Co.'s LIMITx Technology is intended to address the accidental or intentional consumption of multiple tablets. Aversion Technology incorporates gelling ingredients and irritants into tablets to discourage abuse by snorting. Co.'s Impede 1.0 Technology being used in Nexafed Sinus Pressure + Pain contains a proprietary mixture of inactive ingredients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Clemens Peter A |
Senior VP & CFO |
• – – |
2020-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,334 |
364,467 |
|
- |
|
| Brzeczko Albert W |
VP Pharmaceutical Sciences APT |
• – – |
2020-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,334 |
325,334 |
|
- |
|
| Emigh James F |
VP, Corporate Development |
• – – |
2020-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,667 |
444,327 |
|
- |
|
| Skelly William G |
Director |
– • – |
2020-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
83,333 |
337,867 |
|
- |
|
| Jones Robert B |
President & CEO |
• – – |
2020-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,667 |
426,222 |
|
- |
|
| Thangaraj Immanuel |
Director |
– • – |
2019-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
66,666 |
126,192 |
|
- |
|
| Wesson Bruce F/ |
Director |
– • – |
2019-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
66,666 |
520,593 |
|
- |
|
| Ross George K |
Director |
– • – |
2019-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
66,666 |
211,005 |
|
- |
|
| Skelly William G |
Director |
– • – |
2019-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
66,666 |
254,534 |
|
- |
|
| Thangaraj Immanuel |
Director |
– • – |
2018-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,714 |
59,526 |
|
- |
|
| Skelly William G |
Director |
– • – |
2018-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
59,523 |
187,868 |
|
- |
|
| Ross George K |
Director |
– • – |
2018-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
82,774 |
144,339 |
|
- |
|
| Wesson Bruce F/ |
Director |
– • – |
2018-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
59,523 |
453,927 |
|
- |
|
| Galen Partners III L P |
Former 10% owner |
– – – |
2017-12-14 |
4 |
S |
$0.10 |
$219,573 |
I/I |
(2,195,734) |
0 |
|
- |
|
| Skelly William G |
Director |
– • – |
2017-12-14 |
4 |
B |
$0.10 |
$10,000 |
D/D |
100,000 |
128,345 |
2.39 |
- |
|
| Emigh James F |
VP Corporate Development |
• – – |
2017-12-14 |
4 |
B |
$0.10 |
$40,000 |
D/D |
400,000 |
439,660 |
2.74 |
- |
|
| Ross George K |
Director |
– • – |
2017-12-14 |
4 |
B |
$0.10 |
$5,000 |
D/D |
50,000 |
61,565 |
2.39 |
- |
|
| Wesson Bruce F/ |
Director |
– • – |
2017-12-14 |
4 |
B |
$0.10 |
$33,573 |
D/D |
335,734 |
394,404 |
2.39 |
- |
|
| Brzeczko Albert W |
VP Technical Affairs - APT |
• – – |
2017-12-14 |
4 |
B |
$0.10 |
$30,000 |
D/D |
300,000 |
316,000 |
2.74 |
- |
|
| Clemens Peter A |
Senior VP and CFO |
• – – |
2017-12-14 |
4 |
B |
$0.10 |
$30,000 |
D/D |
300,000 |
355,182 |
2.74 |
- |
|
| Jones Robert B |
President and CEO |
• • – |
2017-12-14 |
4 |
B |
$0.10 |
$40,000 |
D/D |
400,000 |
412,555 |
2.81 |
- |
|
| Seiser Robert A |
VP, Controller & Treasurer |
• – – |
2017-12-14 |
4 |
B |
$0.10 |
$30,000 |
D/D |
300,000 |
322,490 |
2.74 |
- |
|
| Brzeczko Albert W |
VP Technical Affairs - APT |
• – – |
2017-08-29 |
4 |
B |
$0.47 |
$1,880 |
D/D |
4,000 |
16,000 |
2.66 |
- |
|
| Brzeczko Albert W |
VP Technical Affairs - APT |
• – – |
2017-08-28 |
4 |
B |
$0.45 |
$909 |
D/D |
2,000 |
12,000 |
2.66 |
- |
|
| Brzeczko Albert W |
VP Technical Affairs - APT |
• – – |
2017-08-25 |
4 |
B |
$0.48 |
$2,304 |
D/D |
4,800 |
10,000 |
2.66 |
- |
|
109 Records found
|
|
Page 3 of 5 |
|
|
